摘要
目的探讨溴己新联合头孢他啶治疗慢性阻塞性肺疾病(COPD)患者对气道黏液分泌及免疫功能的影响。方法选取2017年3月至2020年3月本院收治的60例COPD患者作为研究对象,按照随机数表法分为联合组与对照组,每组30例。对照组采用头孢他啶治疗,联合组在对照组基础上加用溴己新治疗。比较两组治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、最高呼气流速(PEF)]、慢性阻塞性肺病评估测试(CAT)评分、气道黏液分泌(Muc5ac)及免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、呼吸力学指标[气道峰压(PIP)、呼吸做功(WOB)、气道阻力(Raw)、动态顺应性(Cdyn)]及不良反应发生情况。结果治疗后,两组FVC、FEV_(1)均大于治疗前,PEF均快于治疗前,CAT评分均低于治疗前,且联合组FVC、FEV_(1)均大于对照组,PEF快于对照组,CAT评分低于对照组,差异有统计学意义(P<0.05)。治疗后,两组Muc5ac、CD8^(+)水平均低于治疗前,CD4^(+)水平、CD4^(+)/CD8^(+)均高于治疗前,且联合组Muc5ac、CD8^(+)水平均低于对照组,CD4^(+)水平、CD4^(+)/CD8^(+)均高于对照组,差异有统计学意义(P<0.05)。治疗后,两组PIP、WOB均低于治疗前,Raw均小于治疗前,Cdyn高于治疗前,且联合组PIP、WOB低于对照组,Raw小于对照组,Cdyn高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论溴己新联合头孢他啶治疗COPD患者疗效显著,可增强患者肺功能,促进免疫功能恢复,纠正呼吸力学指标,安全性较高,值得临床推广应用。
Objective To explore the effect of bromhexine combined with ceftazidime on airway mucus secretion and immune function in patients with chronic obstructive pulmonary disease(COPD).Methods 60 COPD patients admitted to our hospital from March 2017 to March 2020 were selected as the research subjects,and they were divided into the combined group and the control group according to random number table method,with 30 cases in each group.The control group was treated with ceftazidime,and the combined group was treated with bromhexine on the basis of the control group,the pulmonary function indexs(forced vital capacity[FVC],forced expiratory volume in one second[FEV_(1)],maximum expiratory flow rate[PEF]),chronic obstructive pulmonary disease assessment test(CAT)score,airway mucus secretion(Muc5ac),immune function indexes(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and respiratory mechanics indexes(peak airway pressure[PIP],work done by breathing[WOB],the airway resistance[Raw],the dynamic compliance[Cdyn])before and after treatment were compared between the two groups.Results After treatment,FVC,FEV_(1)of the two groups were larger than before treatment,PEF were faster than before treatment,and CAT scores were lower than before treatment,and FVC,FEV_(1)in the combined group were larger than those in the control group,PEF was faster than that in the control group,and CAT scores were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,Muc5ac and CD8^(+)levels of the two groups were lower than before treatment,CD4^(+)level and CD4^(+)/CD8^(+)were higher than before treatment,and Muc5ac and CD8^(+)levels in the combined group were lower than those in the control group,and CD4^(+)level and CD4^(+)/CD8^(+)were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,PIP and WOB of the two groups were lower than before treatment,Raw were smaller than before treatment,Cdyn was higher than before treatment,and PIP and WOB in the combined group were lower than those in the control group,Raw were smaller than the control group,Cdyn was higher than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Bromhexine combined with ceftazidime in the treatment of COPD patients can enhance lung function,promote the recovery of immune function,and correct respiratory mechanics indexes,which is safe and should be paid attention to in clinic.
作者
邱饶元
周蓓
刘琼霞
QIU Raoyuan;ZHOU Bei;LIU Qiongxia(Department of Respiratory and Critical Care Medicine,First Affiliated Hospital of Jiangxi Medical College,Shangrao,Jiangxi,334000,China)
出处
《当代医学》
2023年第24期60-63,共4页
Contemporary Medicine
关键词
溴己新
头孢他啶
慢性阻塞性肺疾病
Bromhexine
Ceftazidime
Chronic obstructive pulmonary disease
